Rachna Shroff, MD, details key data from the phase III GASTFOX study comparing FOLFOX to docetaxel (TFOX) in the first line treatment of advanced gastric cancer.
Durvalumab Plus Chemo Continues to Improve Survival in Biliary Tract Cancer
April 16th 2024Results from a 3-year follow-up of the TOPAZ-1 trial showed that treatment with durvalumab plus chemotherapy in advanced biliary tract cancer continued to improve overall survival vs chemotherapy alone.
Read More